Easton Pharmaceuticals executives, John K. Easton and Mr. Lee Hendelson have mutually agreed to step down from the company. The company has accepted the resignations of Mr. John K. Easton from his position as Chief Executive officer and chairman of the board, and the resignation of Mr. Hendelson as Chief Financial officer allowing for both individuals to undertake other business opportunities. The company announced Mr. John Adams, age 53, a resident of the UK and the European Union, has accepted the position of Chief Executive officer and President, while Mr. Walter Falinski assumes the position of Chief Financial officer. Mr. Adams possesses a strong background in the field of alternative therapies and treatments, as well as holding a strong belief that many common and serious ailments can be treated with non evasive natural herbal remedies.

Easton Pharmaceuticals Inc. announced that John Mitchell has agreed to join the company as Vice President of Sales - North America. Mr. Mitchell brings years of pharmaceutical sales and marketing experience to compliment Easton Pharmaceuticals management team. Mr. Mitchell has more than 30 years of sales and marketing experience, holding V.P. of Sales positions for several leading North American pharmaceutical and consumer products companies. Mitchell developed and implemented contract agreements for consumer promotions and OEM products for Bayer, Roche Diagnostics, Eli Lilly, Abbott, Medisense, and Lifescan, a division of J&J. As Vice President of Sales - North America, Mr. Mitchell will create and direct key sales and marketing programs, including direct to consumer and direct response marketing plans from product sourcing, packaging, label and product claim review, and full retail sales and marketing support. Mr. Mitchell will be leveraging his extensive sales channel contacts to help Easton Pharmaceuticals build key retail bridges to all major U.S and Canadian retailers, include CVS, Walgreens, GNC, Wal-Mart plus many other retail outlets.

Easton Pharmaceuticals Inc. announced the company has entered Into Discussions with 2 groups to distribute Viorra In South East Asia and surrounding markets. As is the case in Mexico and other Latin American markets, East Asia represents a huge opportunity for VIORRA and the companies various other products based around its proprietary transdermal delivery system. Presently the company has entered into discussions with two groups for the sale and distribution of VIORRA. Any agreements will involve an upfront payment to Easton, presently being discussed by all parties.